IRADIMED CORPORATION

NasdaqGM:IRMD Stok Raporu

Piyasa değeri: US$1.2b

IRADIMED Gelecekteki Büyüme

Future kriter kontrolleri 1/6

IRADIMED kazanç ve gelirinin sırasıyla yıllık 10.9% ve 9.6% oranında artması tahmin edilirken, EPS'nin yıllık 10.7% oranında büyümesi bekleniyor.

Anahtar bilgiler

10.9%

Kazanç büyüme oranı

10.70%

EPS büyüme oranı

Medical Equipment kazanç büyümesi16.1%
Gelir büyüme oranı9.6%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme07 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Anlatı Güncellemesi • Apr 30

IRMD: 2026 Dividend And Guidance Will Anchor Bullish Re Rating

Analysts nudged their price targets for IRADIMED higher, with recent Street research citing supportive views on the business. These views help explain the updated fair value of $118.67 along with a slightly adjusted discount rate and forward P/E assumptions.
Anlatı Güncellemesi • Apr 12

IRMD: 2026 Dividend And Guidance Will Support Bullish Re-Rating

Analysts have trimmed their fair value estimate for IRADIMED from about $120 to roughly $118.67, citing revised assumptions for revenue growth, profit margins and future P/E. At the same time, recent Street research, including fresh bullish initiations and higher price targets, continues to support a constructive view on the stock.
Anlatı Güncellemesi • Mar 26

IRMD: 2026 Guidance And Dividend Will Support Higher Price Re-Rating

Analysts have lifted their price target on IRADIMED by a double digit dollar amount, citing updated valuation work that reflects refined assumptions, including a fair value of $120, a discount rate of 7.69%, revenue growth of 9.70%, a profit margin of 27.77% and a future P/E of 58.53. Analyst Commentary Recent research points to a tighter alignment between IRADIMED's valuation work and updated assumptions on growth, profitability and the P/E investors may be willing to pay.
Anlatı Güncellemesi • Mar 11

IRMD: 2026 Guidance And Dividend Will Support Higher P/E Repricing

Narrative Update on IRADIMED The analyst price target on IRADIMED has been raised by $20 to $120. Analysts cite updated valuation work that incorporates a slightly higher discount rate and future P/E assumption, along with recent Street research that supports the new level.
Anlatı Güncellemesi • Feb 25

IRMD: 2026 Guidance And Dividends Will Support Higher Earnings Multiple

Analysts have lifted their fair value estimate for IRADIMED from $99 to $120, citing updated assumptions around slightly different revenue growth, profit margin expectations, discount rate, and a higher future P/E. These revisions align with recent Street price target increases reported by firms such as Lake Street and Roth Capital.
Anlatı Güncellemesi • Feb 10

IRMD: Stable Outlook Will Rely On 2026 Guidance And Dividend Support

Analysts have kept their price target for IRADIMED effectively unchanged at $99.00. They cite only marginal tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions rather than any shift in their core view on the company.
Anlatı Güncellemesi • Jan 27

IRMD: Record Backlog And Raised Guidance Will Support Premium Yet Balanced Outlook

Narrative Update Analysts have nudged their price targets for IRADIMED higher into a US$98 to US$100 range, reflecting updated forward estimates, a record backlog, the recent beat and raise quarter, and expectations tied to the 3870 IV Pump launch. Analyst Commentary Analysts updating their models for IRADIMED are broadly constructive, with recent research focused on how the latest quarter and product pipeline translate into earnings power and valuation support.
Anlatı Güncellemesi • Jan 12

IRMD: Raised Guidance And Backlog Support Premium While Risks Keep Outlook Balanced

Narrative Update Introduction Analysts have lifted their price expectations for IRADIMED to a range of about $98 to $100, citing higher forward estimates, a record backlog that supports near term visibility, and confidence around the 3870 IV Pump launch as key reasons for the updated targets. Analyst Commentary Recent Street research on IRADIMED reflects a clear tilt toward optimism, with price targets lifted into the high double digits following the latest quarterly update.
Anlatı Güncellemesi • Dec 14

IRMD: Raised Guidance And Backlog Will Support Premium Amid Execution Risks

Analysts have nudged their average price target on IRADIMED higher, to a level just under $100 per share from the low $90s, citing stronger than expected Q3 results, raised full year guidance, and growing confidence that a robust backlog and upcoming product launches will support sustained growth. Analyst Commentary Bullish analysts highlight that the recent upside surprise on both revenue and earnings, along with raised full year guidance, reinforces a view that IRADIMED is executing ahead of prior expectations and can support a higher valuation multiple.
Anlatı Güncellemesi • Nov 29

IRMD: Raised Guidance And Strong Backlog Will Maintain Premium Despite Execution Risks

IRADIMED’s analyst price target has been raised from $90 to a range approaching $100 per share. Analysts cite the company’s recent sales and earnings outperformance, increased full-year guidance, and strong prospects from product innovation and backlog growth.
Anlatı Güncellemesi • Nov 15

IRMD: Raised Guidance And Record Backlog Are Set To Drive Continued Momentum

Analysts have raised their price target for IRADIMED significantly, from $82.50 to $99.00. They cited stronger-than-expected quarterly results, improved guidance, and a robust outlook driven by a growing backlog and product innovation.
Anlatı Güncellemesi • Nov 01

IRMD: Index Addition and Strong Margins Will Support Measured Upside

Analysts have raised their price target for IRADIMED from $73.50 to $82.50. They cite modest improvements in projected profit margins and valuation multiples as key drivers behind the adjustment.
Analiz Makalesi • Oct 09

Should You Be Adding IRADIMED (NASDAQ:IRMD) To Your Watchlist Today?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analiz Makalesi • Aug 13

IRADIMED CORPORATION's (NASDAQ:IRMD) Shares Climb 27% But Its Business Is Yet to Catch Up

Despite an already strong run, IRADIMED CORPORATION ( NASDAQ:IRMD ) shares have been powering on, with a gain of 27% in...
Analiz Makalesi • Aug 08

IRADIMED's (NASDAQ:IRMD) Profits May Not Reveal Underlying Issues

NasdaqGM:IRMD 1 Year Share Price vs Fair Value Explore IRADIMED's Fair Values from the Community and select yours The...
Analiz Makalesi • Jun 01

Shareholders Would Enjoy A Repeat Of IRADIMED's (NASDAQ:IRMD) Recent Growth In Returns

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
User avatar
Yeni Anlatı • Sep 24

Innovative IV Pumps And Monitor Expansion Set To Spearhead Revenue Surge And Enhance Profit Margins

Introduction of the new 3870 IV pump and expansion in the Monitor business signal potential significant revenue growth and increases in product line revenue.
Analiz Makalesi • Aug 08

IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

Despite announcing strong earnings, IRADIMED CORPORATION's ( NASDAQ:IRMD ) stock was sluggish. Our analysis uncovered...
Analiz Makalesi • Feb 23

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Analiz Makalesi • Feb 07

Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...
Analiz Makalesi • Nov 06

Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...
Analiz Makalesi • Oct 13

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

Key Insights Using the 2 Stage Free Cash Flow to Equity, IRadimed fair value estimate is US$36.84 IRadimed's US$37.31...
Analiz Makalesi • Feb 05

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

While IRadimed Corporation ( NASDAQ:IRMD ) might not be the most widely known stock at the moment, it led the NASDAQCM...
Seeking Alpha • Oct 10

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

Iradimed (NASDAQ:IRMD) said it withdrew its 510(K) application seeking U.S. Food and Drug Administration (FDA) approval of its next-generation intravenous (IV) infusion pump system, MRidium 3870; and reported preliminary results for Q3. "The FDA requested additional information that was not feasible to provide within FDA's review deadline; therefore, we decided to withdraw our application to provide us more time to understand and resolve the FDA’s concerns," said Iradimed President and CEO Roger Susi in an Oct. 10 press release. In addition, Iradimed noted that Q3 revenue is expected to be ~$13.4M, up 23% Y/Y as per preliminary results. Consensus Revenue Estimate for Q3 (one analyst) is $13.17M. "These third quarter preliminary results represent our highest revenue quarter," Susi noted. "Orders booked in the quarter exceeded our shipments as we continue to add to our extensive backlog. Domestic unit orders booked in the quarter for our current MRidium 3860 Infusion Pump System were the highest over the last three years, demonstrating the continued strong demand for this product." The company develops Magnetic Resonance Imaging (MRI)-compatible medical devices.
Seeking Alpha • Aug 23

IRadimed: Record Revenue Could Translate To Share Price Appreciation

The share price declined due to a sales slowdown during the height of the pandemic. The company has reported record revenues for the past three consecutive quarters. The stock sold off in 2019 due to regulatory concerns, but the company continued to report record revenues. The stock price bounced back to reach new highs in 2019, and all signs are that history will repeat itself as the fundamental picture remains sound. IRadimed (IRMD) develops, markets, and distributes non-magnetic Medical Resonance Imaging ("MRI") compatible medical devices, accessories, and related services. IRMD is a profitable company that is enjoying increasing demand for its products and is exploiting the opportunity by adding new products. The company has a monopoly as there aren't any direct competitors and it is unlikely that any will come about. No one else is marketing an FDA-approved non-magnetic, MRI-compatible medical device. The recent stock price decline is offering an excellent opportunity to initiate a position or to add shares for an investor interested in a growth stock. My investment thesis: The company is reporting record revenues that exceed the pre-covid time period, but the share price is still 65% below the high. I believe the stock price will follow the strong fundamental picture. I first wrote about the company in 2019 as I saw a disconnect between the stock's fundamentals and the technicals. IRMD was on its third consecutive quarter of record revenues but the stock price had declined about 50%. History is repeating itself for IRMD as the company has again recorded three consecutive quarters of record revenues but the stock price hasn't responded in kind. A comparison of the 2019 and the present charts illustrate similar technical pictures. Despite the reason sell-off the stock price is nearly double now from when my first article was published. I'll follow the technical illustration with a look at the fundamentals which support the stock price resuming its pre-covid uptrend. 2019 chart 2019 chart (Y CHARTS) Present chart IRMD data by YCharts The stock is off 65% from its high of $56/share. The fundamentals point to the stock price climbing back up and reaching new highs. Earnings The company recently reported second-quarter revenue of $12.7 million, nearly a 30% increase over the second quarter of last year, and earnings of $0.26, 116% higher than for the same period in the prior year. It was also reported that bookings were at record levels, setting up continued revenue growth going forward. Management provided guidance of revenue of $13.1 million to $13.3 million for the third quarter and for the full 2022 revenue of $52.5 million to $53.2 million, about 27% higher than for the previous year and higher than pre-covid revenue. Revenues for 2023 could top $70 million if the company continues growing at the same pace. It's possible that the growth rate could accelerate as the company has increased its sales staff and introduced a new product. Share info and valuation There are about 12 million shares. Institutions own about half while insiders own about 43% of the shares. The market cap is $447 million. The company last reported $2.35 million in debt and $52.16 million in cash resulting in an EV of $397 million. The company has sufficient funds to maintain its operations and also make an acquisition if management so desires. IRMD trades at high multiples at first glance but not so when compared to its peer group. IRMD enjoys better margins and therefore the higher P/S and P/B ratios are justified. There's also a premium that IRMD stock can command as the company is a virtual monopoly. IRMD Med. Device Ind. Gross Margin 76% 54% Ebit Margin 26% 16% Price to Sales 6.25 4.04 Price to Book 6.77 4.37 Price to Earnings 35.0 55.39 Compiled by the author from data from CSI Markets Moat The stock price drop in 2019 was due to regulatory compliance issues in Europe and in the U.S. The European Union equivalent of the U.S. FDA found a technical non-conformity with the IRMD MRI compatible patient vital signs monitor. The company received a warning letter from the FDA in 2014 pursuant to a routine inspection that identified eight areas of concern. The warning letter had not been closed until October 2019 and the issue clouded IRMD's future and cast doubt on investors. A great indicator of IRMD's dominance is that Bayer (BAYZF) now offers IRMD non-metallic, MRI-compatible products on its website after stopping production of its own non-magnetic, MRI-compatible devices due to many recalls and FDA warnings. The only other previous IRMD competitor that I could find was Nebion which was also unable to overcome FDA recalls. The Bayer and Nebion experiences and the regulatory hurdles that IRMD has had to clear, point out the difficulties in maintaining regulatory compliance and serve as a moat. A new company seeking to enter IRMD's space would need at least three years to gain FDA clearance. Products The flagship product is a non-magnetic MRI-compatible MRI pump, the MRidium 3860, which serves patients too ill to be taken off intravenous medication and young children who require medication in order to remain still during a scan. The 3860 was FDA approved in 2009. MRidium 3860 (IRadimed website) The FDA approved the company's second commercial device, a non-magnetic MRI-compliant patient monitor system in 2017, the IRadimed 3880. This device is the only portable MRI-compatible patient vital sign monitor allowing for patient monitoring as the patient is moved throughout the hospital. Pumps are the bread and butter of IRMD's business. The monitor is bundled with the pump and offered as a more complete solution. IRadimed The company also offers disposable components, various available upgrades to meet customer needs, and offers extended maintenance contracts. The disposable components and maintenance products provide recurring revenue. The company does not break out what percentage of revenue is recurring. I estimate it to be about 25% of total revenue. A third product, a magnetic detection device has had a delayed introduction due to the pandemic, but sales began this quarter. This device is designed for placement at the entrance to MRI rooms to ensure that magnetic material is detected before it is allowed to enter the room. For anyone not familiar with what happens with magnetic material during an MRI scan please click here. IRadimed

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:IRMD - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20281133218301
12/31/20271012822282
12/31/2026912518232
3/31/202686242429N/A
12/31/202584221725N/A
9/30/202581211425N/A
6/30/202578211327N/A
3/31/202575201426N/A
12/31/202473191726N/A
9/30/202471191724N/A
6/30/202469191316N/A
3/31/202468181113N/A
12/31/20236617513N/A
9/30/20236316513N/A
6/30/20236015715N/A
3/31/20235614513N/A
12/31/20225313810N/A
9/30/20225013910N/A
6/30/20224812910N/A
3/31/202245101112N/A
12/31/20214291111N/A
9/30/20213861010N/A
6/30/202135588N/A
3/31/202132156N/A
12/31/202032156N/A
9/30/202034477N/A
6/30/202036589N/A
3/31/202039101011N/A
12/31/20193910N/A10N/A
9/30/2019368N/A10N/A
6/30/2019348N/A7N/A
3/31/2019327N/A6N/A
12/31/2018306N/A7N/A
9/30/2018295N/A5N/A
6/30/2018273N/A6N/A
3/31/2018252N/A5N/A
12/31/2017230N/A3N/A
9/30/2017221N/A4N/A
6/30/2017243N/A6N/A
3/31/2017295N/A7N/A
12/31/2016327N/A9N/A
9/30/2016358N/A10N/A
6/30/2016359N/A9N/A
3/31/2016338N/A9N/A
12/31/2015318N/A8N/A
9/30/2015265N/A4N/A
6/30/2015224N/A3N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: IRMD 'nin tahmini kazanç büyümesi (yıllık 10.9% ) tasarruf oranının ( 3.5% ) üzerindedir.

Kazançlar ve Piyasa: IRMD şirketinin kazançlarının (yıllık 10.9% ) US pazarından (yıllık 16.8% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: IRMD şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: IRMD şirketinin gelirinin (yıllık 9.6% ) US pazarından (yıllık 11.6% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: IRMD şirketinin gelirinin (yıllık 9.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: IRMD 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/21 23:16
Gün Sonu Hisse Fiyatı2026/05/21 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

IRADIMED CORPORATION 4 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Lawrence SolowCJS Securities, Inc.
Ilya ZubkovFreedom Broker
Frank TakkinenLake Street Capital Markets, LLC